Fulcrum Therapeutics to Participate in Upcoming December Conferences

Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [2] - The company will participate in multiple healthcare conferences in December 2024, including the Piper Sandler 36th Annual Healthcare Conference, Citi 2024 Global Healthcare Conference, and Evercore ISI 7th Annual HealthCONx Conference [1] Company Overview - Fulcrum Therapeutics specializes in small molecules aimed at improving the lives of patients with rare diseases that have high unmet medical needs [2] - The lead program in clinical development is pociredir, which is designed to increase fetal hemoglobin expression for treating sickle cell disease [2] - The company employs proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene misexpression [2]